Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MRVI - US56600D1072 - Common Stock

3.92 USD
+0.23 (+6.23%)
Last: 1/16/2026, 8:00:01 PM
3.95 USD
+0.03 (+0.77%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

2

Overall MRVI gets a fundamental rating of 2 out of 10. We evaluated MRVI against 57 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year MRVI has reported negative net income.
  • In the past year MRVI has reported a negative cash flow from operations.
  • In multiple years MRVI reported negative net income over the last 5 years.
  • Each year in the past 5 years MRVI had a positive operating cash flow.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • MRVI has a Return On Assets (-14.28%) which is comparable to the rest of the industry.
  • MRVI has a worse Return On Equity (-49.40%) than 70.18% of its industry peers.
Industry RankSector Rank
ROA -14.28%
ROE -49.4%
ROIC N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • With a Gross Margin value of 20.86%, MRVI is not doing good in the industry: 82.46% of the companies in the same industry are doing better.
  • MRVI's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

  • MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MRVI has more shares outstanding
  • MRVI has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRVI has been reduced compared to a year ago.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 1.10, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.10, MRVI is not doing good in the industry: 63.16% of the companies in the same industry are doing better.
  • MRVI has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
  • MRVI has a Debt to Equity ratio of 1.29. This is amonst the worse of the industry: MRVI underperforms 82.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Altman-Z 1.1
ROIC/WACCN/A
WACC12.08%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 5.29 indicates that MRVI has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.29, MRVI belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
  • A Quick Ratio of 4.56 indicates that MRVI has no problem at all paying its short term obligations.
  • MRVI has a Quick ratio of 4.56. This is amongst the best in the industry. MRVI outperforms 82.46% of its industry peers.
Industry RankSector Rank
Current Ratio 5.29
Quick Ratio 4.56
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

  • MRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -900.00%.
  • The Revenue for MRVI has decreased by -30.56% in the past year. This is quite bad
  • The Revenue has been growing by 12.61% on average over the past years. This is quite good.
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-30.56%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-36.15%

3.2 Future

  • Based on estimates for the next years, MRVI will show a very negative growth in Earnings Per Share. The EPS will decrease by -16.46% on average per year.
  • MRVI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.97% yearly.
EPS Next Y-225.47%
EPS Next 2Y-45.72%
EPS Next 3Y-12.45%
EPS Next 5Y-16.46%
Revenue Next Year-28.69%
Revenue Next 2Y-11.82%
Revenue Next 3Y-5.74%
Revenue Next 5Y-0.97%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRVI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • MRVI's earnings are expected to decrease with -12.45% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.72%
EPS Next 3Y-12.45%

More info and screens

0

5. Dividend

5.1 Amount

  • MRVI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (1/16/2026, 8:00:01 PM)

After market: 3.95 +0.03 (+0.77%)

3.92

+0.23 (+6.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-16
Inst Owners76.87%
Inst Owner Change-0.06%
Ins Owners5.54%
Ins Owner Change1.19%
Market Cap1.00B
Revenue(TTM)192.28M
Net Income(TTM)-121.24M
Analysts76.47
Price Target3.93 (0.26%)
Short Float %11.99%
Short Ratio9.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.34%
Min EPS beat(2)-10.61%
Max EPS beat(2)3.93%
EPS beat(4)1
Avg EPS beat(4)-15.88%
Min EPS beat(4)-47.06%
Max EPS beat(4)3.93%
EPS beat(8)3
Avg EPS beat(8)-14.07%
EPS beat(12)4
Avg EPS beat(12)-40.43%
EPS beat(16)8
Avg EPS beat(16)-26.46%
Revenue beat(2)0
Avg Revenue beat(2)-9.3%
Min Revenue beat(2)-16.71%
Max Revenue beat(2)-1.9%
Revenue beat(4)1
Avg Revenue beat(4)-4.39%
Min Revenue beat(4)-16.71%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.71%
Revenue beat(12)4
Avg Revenue beat(12)-2.4%
Revenue beat(16)7
Avg Revenue beat(16)-1.24%
PT rev (1m)0%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.8%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.21
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.75
BVpS0.96
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.28%
ROE -49.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.86%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.54%
Cap/Sales 9.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.29
Quick Ratio 4.56
Altman-Z 1.1
F-Score5
WACC12.08%
ROIC/WACCN/A
Cap/Depr(3y)93.62%
Cap/Depr(5y)87.93%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-225.47%
EPS Next 2Y-45.72%
EPS Next 3Y-12.45%
EPS Next 5Y-16.46%
Revenue 1Y (TTM)-30.56%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-36.15%
Revenue Next Year-28.69%
Revenue Next 2Y-11.82%
Revenue Next 3Y-5.74%
Revenue Next 5Y-0.97%
EBIT growth 1Y-193.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2317.03%
EBIT Next 3Y134.85%
EBIT Next 5Y84.28%
FCF growth 1Y-141.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.7%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%

MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ

What is the ChartMill fundamental rating of MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRVI.


What is the valuation status for MRVI stock?

ChartMill assigns a valuation rating of 0 / 10 to MARAVAI LIFESCIENCES HLDGS-A (MRVI). This can be considered as Overvalued.


Can you provide the profitability details for MARAVAI LIFESCIENCES HLDGS-A?

MARAVAI LIFESCIENCES HLDGS-A (MRVI) has a profitability rating of 1 / 10.


What is the expected EPS growth for MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?

The Earnings per Share (EPS) of MARAVAI LIFESCIENCES HLDGS-A (MRVI) is expected to decline by -225.47% in the next year.